PharmEng International Inc.

PharmEng International Inc.

October 17, 2005 09:00 ET

PharmEng Opens Offices, Announces $1.7m U.S. Contract In Raleigh, North Carolina

TORONTO, ONTARIO--(CCNMatthews - Oct. 17, 2005) - PharmEng International Inc. (TSX VENTURE:PII), a full-service consulting and contract manufacturing company, today announced the opening of the Raleigh office in North Carolina. Concurrent with the opening, the Company announced the hiring of a Director for the USA operation and the securing of over US$1.7 M in contracts for the N. Carolina operations.

The Raleigh office is situated on the edge of North Carolina's Research Triangle Park, home to over 100 research and development-oriented companies including pharmaceutical, biotechnology and biopharmaceutical organizations. The area is strategic to the central east coast region of the USA. Located approximately five miles from Raleigh Durham International Airport, the Raleigh location provides convenient access and cost-efficient travel allowing access to other major pharmaceutical and biotechnology hubs such as Washington DC and the Piedmont Triad area.

To head up the offices, Shelley Preslar has been hired as Director, Raleigh, Pharmaceutical and Biotechnology Division - joining the PharmEng USA Inc. division on September 26, 2005. Ms. Preslar will be instrumental in the start-up and expansion of the offices both locally and in related sectors throughout the USA. Prior to joining PharmEng, Shelley Preslar was the South East USA Senior Project Manager for a Regulatory and Validation Compliance Consulting firm.

The Raleigh offices, through the wholly owned subsidiary PharmEng USA Inc., have been awarded a contract for services exceeding US$1.7 M over the ensuing year. This commitment is expected to grow into additional services provided by PharmEng.

"Our company has consistently demonstrated that we can compete successfully in the international marketplace. Our people, with their depth of knowledge, provide our clients with invaluable access to a wide range of subject matter experts." commented Alan Kwong, CEO and Chairman of PharmEng International Inc. "We are the added bench strength when our clients need to go deep in the regulatory and validation compliance arena." concluded Mr. Kwong.

About PharmEng International Inc.

PharmEng International Inc., headquartered in Toronto, Canada, is a full-service consulting and contract manufacturing company that serves the pharmaceutical, biotechnology and medical device industries in North America and internationally. Consulting services include project management, engineering, GMP, validation, calibration, regulatory compliance and certified training. Contract manufacturing includes pharmaceutical support, formulation development, laboratory testing, and finished solid dosage and liquid products. Building on a foundation of over seven years of successful consulting, PharmEng in combination with its wholly owned manufacturing subsidiary, Keata, has evolved into a full service pharmaceutical company. PharmEng's shares trade on the TSX Venture Exchange under the symbol PII. For more information about PharmEng, please visit the Company's website at


Certain statements in this press release may include "forward-looking" statements which involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of PharmEng to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this press release, such statements use such words as "may", "will", "expect", "anticipate", "project", "believe", "plan", and other similar terminology. The risks and uncertainties are detailed from time to time in reports filed by PharmEng with the securities regulatory authorities in all of the provinces and territories of Canada. New risk factors may arise from time to time and it is not possible for management to predict all of those risk factors or the extent to which any factor or combination of factors may cause actual results, performance and achievements of PharmEng to be materially different from those contained in forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction actual results.

Contact Information